摘要
Abstract
Objective To evaluate the effectiveness,safety,and economic efficiency of lemborexant in the treatment of insomnia.Methods PubMed,The Cochrane Library,CNKI,Wanfang Database,VIP,and health technology assessment(HTA)websites were searched to collect systematic reviews/meta-analyses,pharmacoeconomic studies,and HTA reports on lemborexant for insomnia.After data extraction and quality assessment,a descriptive analysis was conducted on the results of the included studies.Results A total of 17 articles were included,comprising 16 systematic reviews/meta-analyses and one pharmacoeconomic study.In terms of effectiveness,compared with placebo,lemborexant significantly reduced latency to persistent sleep,wake time after sleep onset,insomnia severity index,and sleep onset latency,and significantly increased sleep efficiency and total sleep time(P＜0.05).Regarding safety,except for the significantly higher risk of somnolence with lemborexant(P＜0.05)had no significant differences in treatment-emergent adverse events(TEAE),TEAE leading to discontinuation,serious TEAE,or the overall risk of adverse events between lemborexant and placebo,suvorexant(P＞0.05).Conclusions Lemborexant is effective and safe in the treatment of insomnia.关键词
莱博雷生/失眠症/双食欲素受体拮抗剂/有效性/安全性/经济性/快速卫生技术评估Key words
Lemborexant/Insomnia/Dual orexin receptor antagonist/Effectiveness/Safety/Economic efficiency/Rapid health technology assessment
